<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678479</url>
  </required_header>
  <id_info>
    <org_study_id>1042-CDD-EAP-3005</org_study_id>
    <nct_id>NCT04678479</nct_id>
  </id_info>
  <brief_title>Ganaxolone Expanded Access Program Compassionate Use</brief_title>
  <acronym>CDD</acronym>
  <official_title>Expanded Access With Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin Dependent Kinase-like 5 Deficiency Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The primary objective is to provide GNX to patients ≥ 2 years with CDD-related seizures who&#xD;
      are refractory to, or intolerant of, standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, long-term, open-label, expanded access protocol of adjunctive GNX&#xD;
      treatment in children, adolescents, and adults with CDD. Patients with inadequate seizure&#xD;
      control on their current anti seizure medications at therapeutic doses will be eligible for&#xD;
      enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>CDKL5 Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>ganaxolone</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Molecular confirmation of a pathogenic CDKL5 variant, early onset, difficult to&#xD;
             control seizures, and neurodevelopmental impairment are required. Male or female&#xD;
             patients aged ≥ 2 years. In the opinion of the investigator, the patient has&#xD;
             inadequate seizure control on current anti-seizure medications at therapeutic doses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Paula Bokesch, MD, FAAP</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Grachev, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juby Philip</last_name>
    <phone>302-559-4320</phone>
    <email>jphilip@marinuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Cintron</last_name>
    <phone>305-956-8271</phone>
    <email>kcintron@marinuspharma.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganaxolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

